Apogee Therapeutics acquired by Abbvie

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing next-generation biological treatments in the field of immunology. The company's research efforts are centered on chronic inflammatory diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other immune-mediated disorders. At the core of its approach lies a cutting-edge platform of novel antibodies designed to offer enhanced efficacy and prolonged duration of action compared to existing treatments. These therapies aim to improve both symptom control and dosing frequency, with a particular emphasis on streamlining patient care pathways. The company's most advanced program is a monoclonal antibody targeting the interleukin-13 pathway, developed to treat atopic dermatitis and other inflammatory diseases. Available clinical data suggest a high potential for efficacy in alleviating skin symptoms and pruritus, as well as a tolerability profile comparable to current standards. A key differentiator of the company's portfolio is the potential for spaced dosing regimens, with intervals of up to several months between injections, which represents a significant advantage in terms of patient comfort and adherence.